These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34910154)

  • 1. Comparative Effectiveness of Biologic Agents Among Black and White Medicare Patients in the US With Metastatic Colorectal Cancer.
    Goel S; Negassa A; Acuna-Villaorduna A
    JAMA Netw Open; 2021 Dec; 4(12):e2136378. PubMed ID: 34910154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Biologic Agents Among Hispanic Patients With Metastatic Colorectal Cancer.
    Patel R; Negassa A; Tolu SS; Acuna-Villaorduna A; Goel S
    Clin Colorectal Cancer; 2024 Mar; 23(1):14-21.e1. PubMed ID: 37919185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer.
    Goel S; Negassa A; Khot A; Goyal D; Guo S; Nandikolla A; Bakirhan K; Polineni R; Shah U; Chaudhary I; Ghalib MH; Rajdev L; Kaubisch A; Chuy J; Aparo S
    Clin Colorectal Cancer; 2017 Dec; 16(4):286-292. PubMed ID: 28412139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
    JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.
    Petito LC; García-Albéniz X; Logan RW; Howlader N; Mariotto AB; Dahabreh IJ; Hernán MA
    JAMA Netw Open; 2020 Mar; 3(3):e200452. PubMed ID: 32134464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.
    Mack CD; Carpenter W; Meyer AM; Sanoff H; Stürmer T
    Cancer; 2012 Jun; 118(11):2925-34. PubMed ID: 22072441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer.
    Obeidat NA; Pradel FG; Zuckerman IH; DeLisle S; Mullins CD
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):343-54. PubMed ID: 20129255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE).
    Polite BN; Sing A; Sargent DJ; Grothey A; Berlin J; Kozloff M; Feng S
    Cancer; 2012 Feb; 118(4):1083-90. PubMed ID: 21800287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
    Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics associated with differences in survival among black and white women with breast cancer.
    Silber JH; Rosenbaum PR; Clark AS; Giantonio BJ; Ross RN; Teng Y; Wang M; Niknam BA; Ludwig JM; Wang W; Even-Shoshan O; Fox KR
    JAMA; 2013 Jul; 310(4):389-97. PubMed ID: 23917289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racial disparity in consultation, treatment, and the impact on survival in metastatic colorectal cancer.
    Simpson DR; Martínez ME; Gupta S; Hattangadi-Gluth J; Mell LK; Heestand G; Fanta P; Ramamoorthy S; Le QT; Murphy JD
    J Natl Cancer Inst; 2013 Dec; 105(23):1814-20. PubMed ID: 24231453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries.
    Green AK; Curry M; Trivedi N; Bach PB; Mailankody S
    JAMA Netw Open; 2021 Feb; 4(2):e210030. PubMed ID: 33625507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in the Incidence of Early-Onset Colorectal Adenocarcinoma Among Black and White US Residents Aged 40 to 49 Years, 2000-2017.
    Montminy EM; Zhou M; Maniscalco L; Penrose H; Yen T; Patel SG; Wu XC; Karlitz JJ
    JAMA Netw Open; 2021 Nov; 4(11):e2130433. PubMed ID: 34751760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing short- and long-term outcomes among black vs white Medicare patients undergoing resection of colorectal cancer.
    Schneider EB; Haider AH; Hyder O; Efron JE; Lidor AO; Pawlik TM
    Am J Surg; 2013 Apr; 205(4):402-8. PubMed ID: 23375764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
    Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
    Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia.
    Delahunty R; Lee M; Wong HL; Johns J; Mckendrick J; Lee B; Kosmider S; Cooray P; Ananda S; Desai J; Tran B; Tie J; Gibbs P; Wong R
    Intern Med J; 2020 Feb; 50(2):165-172. PubMed ID: 30887616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
    Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
    Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
    Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
    JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
    Hsiao FY; Mullins CD; Onukwugha E; Pandya N; Hanna N
    J Am Geriatr Soc; 2011 Sep; 59(9):1717-23. PubMed ID: 21831168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.